Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited)

v3.22.1
Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]        
Net sales $ 290,376 $ 243,552 $ 817,371 $ 672,004
Cost of sales 88,918 75,278 261,225 215,098
Gross margin 201,458 168,274 556,146 456,906
Operating expenses:        
Selling, general and administrative 89,269 82,596 276,137 238,310
Research and development 21,742 17,052 63,992 49,882
Total operating expenses 111,011 99,648 340,129 288,192
Operating income 90,447 68,626 216,017 168,714
Other income (expense) (21,675) (23,272) 6,317 (27,652)
Earnings before income taxes 68,772 45,354 222,334 141,062
Income taxes (benefit) 8,628 (48) 21,150 16,121
Net earnings, including noncontrolling interest 60,144 45,402 201,184 124,941
Net earnings (loss) attributable to noncontrolling interest (595) (380) (9,343) (509)
Net earnings attributable to Bio-Techne 60,739 45,782 210,527 125,450
Other comprehensive income (loss):        
Foreign currency translation adjustments (2,851) (1,142) (9,573) 27,700
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8 7,179 1,288 11,745 5,490
Other comprehensive income (loss) 4,328 146 2,172 33,190
Other comprehensive income (loss) attributable to noncontrolling interest (1) (69) 26 14
Other comprehensive income (loss) attributable to Bio-Techne 4,329 215 2,146 33,176
Comprehensive income attributable to Bio-Techne $ 65,068 $ 45,997 $ 212,673 $ 158,626
Earnings per share attributable to Bio-Techne:        
Basic (in dollars per share) $ 1.55 $ 1.18 $ 5.36 $ 3.24
Diluted (in dollars per share) $ 1.48 $ 1.12 $ 5.12 $ 3.11
Weighted average common shares outstanding:        
Basic (in shares) 39,272 38,856 39,225 38,693
Diluted (in shares) 40,969 40,676 41,073 40,305